(VIANEWS) – Bank7 Corp. (BSVN), Novo Nordisk A/S (NVO), First Community Bankshares (FCBC) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Bank7 Corp. (BSVN)
28.9% sales growth and 21.83% return on equity
Bank7 Corp. operates as a bank holding company for Bank7 that provides banking and financial services to individual and corporate customers in Oklahoma, Kansas, and Texas. It accepts demand, savings, checking, money market, and negotiable order of withdrawal accounts, as well as certificates of deposit. The company also provides commercial real estate, hospitality, energy, and commercial and industrial loans; and consumer loans, such as secured and unsecured term loans and home improvement loans; and residential real estate loans, mortgage banking services, personal lines of credit, loans for the purchase of automobiles, and other installment loans, as well as ATM services. It operates through a network of 9 full-service branches in Oklahoma, the Dallas/Fort Worth, Texas metropolitan area, and Kansas. The company was formerly known as Haines Financial Corp. Bank7 Corp. was incorporated in 2004 and is headquartered in Oklahoma City, Oklahoma.
Earnings Per Share
As for profitability, Bank7 Corp. has a trailing twelve months EPS of $3.22.
PE Ratio
Bank7 Corp. has a trailing twelve months price to earnings ratio of 9.13. Meaning, the purchaser of the share is investing $9.13 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.83%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 40.3%, now sitting on 67.9M for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 44.1% and 31.6%, respectively.
Moving Average
Bank7 Corp.’s worth is above its 50-day moving average of $27.94 and way above its 200-day moving average of $25.11.
2. Novo Nordisk A/S (NVO)
24.1% sales growth and 72% return on equity
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Earnings Per Share
As for profitability, Novo Nordisk A/S has a trailing twelve months EPS of $2.92.
PE Ratio
Novo Nordisk A/S has a trailing twelve months price to earnings ratio of 48.55. Meaning, the purchaser of the share is investing $48.55 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 72%.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Mar 23, 2023, the estimated forward annual dividend rate is 1.77 and the estimated forward annual dividend yield is 1.27%.
Volume
Today’s last reported volume for Novo Nordisk A/S is 1055320 which is 27.13% below its average volume of 1448290.
Sales Growth
Novo Nordisk A/S’s sales growth is 22.5% for the ongoing quarter and 24.1% for the next.
Previous days news about Novo Nordisk A/S(NVO)
- According to Zacks on Wednesday, 8 March, "Some better-ranked stocks in the Medical space are Novo Nordisk A/S (NVO Quick QuoteNVO – Free Report) , Alcon Inc. (ALC Quick QuoteALC – Free Report) and Humana Inc. (HUM Quick QuoteHUM – Free Report) . "
3. First Community Bankshares (FCBC)
17% sales growth and 10.98% return on equity
First Community Bankshares, Inc. operates as the financial holding company for First Community Bank that provides various banking products and services. It offers demand deposit accounts, savings and money market accounts, certificates of deposit, and individual retirement arrangements; commercial, consumer, and real estate mortgage loans, as well as lines of credit; various credit and debit cards, and automated teller machine card services; and corporate and personal trust services. The company also provides wealth management services, including trust management, estate administration, and investment advisory services; and investment management services. It serves individuals and businesses across various industries, such as education, government, and health services; coal mining and gas extraction; retail trade; construction; manufacturing; tourism; and transportation. As of December 31, 2021, the company operated 49 branches, including 17 branches in West Virginia, 23 branches in Virginia, 7 branches in North Carolina, and 2 branches in Tennessee. First Community Bankshares, Inc. was founded in 1874 and is headquartered in Bluefield, Virginia.
Earnings Per Share
As for profitability, First Community Bankshares has a trailing twelve months EPS of $2.84.
PE Ratio
First Community Bankshares has a trailing twelve months price to earnings ratio of 11.24. Meaning, the purchaser of the share is investing $11.24 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.98%.
Yearly Top and Bottom Value
First Community Bankshares’s stock is valued at $31.93 at 00:22 EST, way below its 52-week high of $39.39 and way above its 52-week low of $26.51.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Feb 8, 2023, the estimated forward annual dividend rate is 1.16 and the estimated forward annual dividend yield is 3.65%.
4. Farmers National Banc Corp. (FMNB)
16.4% sales growth and 15.85% return on equity
Farmers National Banc Corp., a financial holding company, operates in the banking, trust, retirement consulting, insurance, and financial management industries. It offers commercial and retail banking services, including checking, savings, and time deposit accounts; commercial, mortgage and installment, and home equity loans; home equity lines of credit, night depository, safe deposit box, money order, bank check, automated teller machine, Internet banking, travel card, E bond transaction, MasterCard and Visa credit cards, brokerage, and other services. The company also provides personal and corporate trust services in the areas of estate settlement, trust administration, and employee benefit plans; retirement services; property and casualty insurance products and services; and various insurance products through licensed representatives, as well as invests in municipal securities. It operates through 47 locations in northeastern region of Ohio and one location in southwestern Pennsylvania. The company was founded in 1887 and is based in Canfield, Ohio.
Earnings Per Share
As for profitability, Farmers National Banc Corp. has a trailing twelve months EPS of $1.79.
PE Ratio
Farmers National Banc Corp. has a trailing twelve months price to earnings ratio of 7.99. Meaning, the purchaser of the share is investing $7.99 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.85%.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Dec 7, 2022, the estimated forward annual dividend rate is 0.68 and the estimated forward annual dividend yield is 4.75%.
Moving Average
Farmers National Banc Corp.’s value is above its 50-day moving average of $14.23 and below its 200-day moving average of $14.42.
5. United Therapeutics Corporation (UTHR)
16% sales growth and 16.61% return on equity
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhance the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing OreniPro, RemoPro, Tyvaso DPI, Trevyent, Ralinepag, and Aurora-GT to treat PAH; Unexisome to treat bronchopulmonary dysplasia; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. It has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin; Caremark, L.L.C. to provide refills of implanted pumps at its infusion centers; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder and Dreamboat devices; and Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Earnings Per Share
As for profitability, United Therapeutics Corporation has a trailing twelve months EPS of $14.93.
PE Ratio
United Therapeutics Corporation has a trailing twelve months price to earnings ratio of 16.4. Meaning, the purchaser of the share is investing $16.4 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.61%.
Sales Growth
United Therapeutics Corporation’s sales growth is 11.4% for the present quarter and 16% for the next.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter is a negative 9.9% and positive 90.5% for the next.
Moving Average
United Therapeutics Corporation’s worth is under its 50-day moving average of $262.40 and higher than its 200-day moving average of $238.73.
6. ITT Corporation (ITT)
8.9% sales growth and 16.52% return on equity
ITT Inc. manufactures and sells engineered critical components and customized technology solutions for the energy, transportation, and industrial markets worldwide. The company operates through three segments: Motion Technologies, Industrial Process, and Connect & Control Technologies. The Motion Technologies segment manufactures brake pads, shims, shock absorbers, and energy absorption components; and sealing technologies primarily for the transportation industry, including passenger cars, light- and heavy-duty commercial and military vehicles, buses, and rail. The Industrial Process segment designs and manufactures industrial pumps, valves, and plant optimization systems; and centrifugal process pumps, twin screw, axials, and positive displacement pumps, and water systems, as well as aftermarket solutions, such as repairs and upgrades services. It serves various customers in industries, such as chemical, oil and gas, mining, and other industrial process markets. The Connect & Control Technologies segment designs and manufactures a range of engineered connectors and specialized control components for critical applications supporting various markets, including aerospace and defense, industrial, transportation, medical, and oil and gas. The connector product portfolio includes electrical connectors, such as circular, rectangular, radio frequency, fiber optic, D-sub miniature, micro-miniature, and cable assemblies; and control products consist of fuel and water pumps, valves, electro-mechanical rotary and linear actuators, and pressure, temperature, limit, and flow switches for various aircraft systems. ITT Inc. was founded in 1920 and is headquartered in White Plains, New York.
Earnings Per Share
As for profitability, ITT Corporation has a trailing twelve months EPS of $4.4.
PE Ratio
ITT Corporation has a trailing twelve months price to earnings ratio of 21.41. Meaning, the purchaser of the share is investing $21.41 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.52%.
Yearly Top and Bottom Value
ITT Corporation’s stock is valued at $94.19 at 00:22 EST, under its 52-week high of $95.18 and way above its 52-week low of $63.77.
Revenue Growth
Year-on-year quarterly revenue growth grew by 13%, now sitting on 2.99B for the twelve trailing months.
7. Hostess Brands (TWNK)
7.4% sales growth and 9.34% return on equity
Hostess Brands, Inc., a packaged food company, develops, manufactures, markets, sells, and distributes fresh sweet baked goods in the United States. It primarily offer a range of snack cakes, donuts, sweet rolls, breakfast pastries, snack pies, and related products. The company operates in two segments, Sweet Baked Goods and In-Store Bakery. The Sweet Baked Goods segment offers fresh and frozen sweet baked goods and bread products under the Hostess, Dolly Madison, Cloverhill, and Big Texas brands, as well as store branded products. The In-Store Bakery segment primarily provides Superior on Main branded eclairs, madeleines, brownies, and iced cookies in the bakery section of grocery and club stores. The company was formerly known as Gores Holdings, Inc. and changed its name to Hostess Brands, Inc. in November 2016. Hostess Brands, Inc. was founded in 1919 and is based in Lenexa, Kansas.
Earnings Per Share
As for profitability, Hostess Brands has a trailing twelve months EPS of $1.18.
PE Ratio
Hostess Brands has a trailing twelve months price to earnings ratio of 20.53. Meaning, the purchaser of the share is investing $20.53 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.34%.
Sales Growth
Hostess Brands’s sales growth is 2.1% for the ongoing quarter and 7.4% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 14.2%, now sitting on 1.36B for the twelve trailing months.
Yearly Top and Bottom Value
Hostess Brands’s stock is valued at $24.23 at 00:22 EST, way below its 52-week high of $29.00 and way above its 52-week low of $19.00.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Hostess Brands’s EBITDA is 3.1.
